| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 61 | 2023 | 2207 | 4.220 |
Why?
|
| Acquired Immunodeficiency Syndrome | 15 | 2023 | 214 | 2.080 |
Why?
|
| Hepatitis C | 7 | 2016 | 120 | 1.580 |
Why?
|
| Anti-HIV Agents | 16 | 2021 | 394 | 1.430 |
Why?
|
| CD4 Lymphocyte Count | 25 | 2022 | 185 | 1.360 |
Why?
|
| Antiretroviral Therapy, Highly Active | 8 | 2017 | 219 | 1.080 |
Why?
|
| Adult | 75 | 2023 | 11034 | 1.070 |
Why?
|
| Puerto Rico | 34 | 2016 | 1352 | 1.050 |
Why?
|
| Cohort Studies | 35 | 2022 | 1422 | 1.050 |
Why?
|
| Middle Aged | 63 | 2023 | 9642 | 0.920 |
Why?
|
| Viral Load | 18 | 2021 | 300 | 0.910 |
Why?
|
| Multimedia | 3 | 2013 | 16 | 0.890 |
Why?
|
| Male | 80 | 2023 | 18870 | 0.890 |
Why?
|
| Female | 80 | 2023 | 19873 | 0.880 |
Why?
|
| Humans | 94 | 2023 | 34853 | 0.770 |
Why?
|
| Canada | 19 | 2023 | 121 | 0.760 |
Why?
|
| Lupus Erythematosus, Systemic | 10 | 2011 | 151 | 0.740 |
Why?
|
| Neoplasms | 8 | 2021 | 1033 | 0.730 |
Why?
|
| North America | 16 | 2022 | 60 | 0.690 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2022 | 37 | 0.660 |
Why?
|
| Sarcoma, Kaposi | 4 | 2022 | 20 | 0.610 |
Why?
|
| Hepatitis B | 3 | 2023 | 39 | 0.560 |
Why?
|
| Risk Factors | 24 | 2022 | 3414 | 0.550 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2016 | 41 | 0.540 |
Why?
|
| Substance Abuse, Intravenous | 6 | 2021 | 123 | 0.540 |
Why?
|
| United States | 25 | 2023 | 3894 | 0.510 |
Why?
|
| Proportional Hazards Models | 13 | 2021 | 423 | 0.490 |
Why?
|
| Liver Neoplasms | 5 | 2021 | 195 | 0.490 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2021 | 147 | 0.470 |
Why?
|
| Lymphoma, AIDS-Related | 2 | 2022 | 13 | 0.460 |
Why?
|
| Risk Reduction Behavior | 2 | 2013 | 121 | 0.450 |
Why?
|
| Body Mass Index | 5 | 2016 | 775 | 0.450 |
Why?
|
| Incidence | 15 | 2021 | 882 | 0.450 |
Why?
|
| HIV | 5 | 2023 | 97 | 0.430 |
Why?
|
| Anus Neoplasms | 3 | 2022 | 47 | 0.410 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2023 | 160 | 0.410 |
Why?
|
| Comorbidity | 12 | 2021 | 606 | 0.410 |
Why?
|
| Myocardial Infarction | 3 | 2019 | 221 | 0.410 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 2011 | 9 | 0.410 |
Why?
|
| Prevalence | 14 | 2022 | 1425 | 0.410 |
Why?
|
| Hepatitis B, Chronic | 2 | 2021 | 11 | 0.400 |
Why?
|
| Anti-Retroviral Agents | 4 | 2023 | 139 | 0.400 |
Why?
|
| Diabetes Mellitus | 6 | 2021 | 465 | 0.400 |
Why?
|
| Health Education | 1 | 2013 | 304 | 0.380 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2010 | 13 | 0.370 |
Why?
|
| Scleroderma, Systemic | 1 | 2010 | 17 | 0.370 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2017 | 251 | 0.360 |
Why?
|
| Hospitalization | 3 | 2022 | 370 | 0.360 |
Why?
|
| Anemia | 3 | 2022 | 45 | 0.350 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2013 | 790 | 0.350 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2008 | 19 | 0.340 |
Why?
|
| Mitral Valve | 1 | 2008 | 22 | 0.340 |
Why?
|
| Aortic Valve | 1 | 2008 | 25 | 0.340 |
Why?
|
| Cross-Sectional Studies | 15 | 2023 | 2561 | 0.340 |
Why?
|
| Aged | 21 | 2021 | 6448 | 0.330 |
Why?
|
| Immune Tolerance | 2 | 2019 | 61 | 0.320 |
Why?
|
| Computer-Assisted Instruction | 1 | 2008 | 27 | 0.320 |
Why?
|
| Drug Prescriptions | 2 | 2023 | 42 | 0.300 |
Why?
|
| Young Adult | 17 | 2019 | 4012 | 0.290 |
Why?
|
| Mortality | 2 | 2005 | 150 | 0.290 |
Why?
|
| Treatment Outcome | 11 | 2016 | 1349 | 0.280 |
Why?
|
| Viremia | 3 | 2021 | 40 | 0.280 |
Why?
|
| Kidney Failure, Chronic | 3 | 2019 | 231 | 0.270 |
Why?
|
| Fibromyalgia | 2 | 2016 | 11 | 0.270 |
Why?
|
| Risk-Taking | 3 | 2015 | 435 | 0.250 |
Why?
|
| Hepatitis C, Chronic | 2 | 2021 | 39 | 0.240 |
Why?
|
| RNA, Viral | 4 | 2021 | 287 | 0.240 |
Why?
|
| Adolescent | 14 | 2019 | 5035 | 0.240 |
Why?
|
| Pneumonia | 1 | 2003 | 50 | 0.230 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2022 | 4 | 0.220 |
Why?
|
| Hodgkin Disease | 1 | 2022 | 11 | 0.210 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 19 | 0.210 |
Why?
|
| Multivariate Analysis | 8 | 2021 | 570 | 0.210 |
Why?
|
| Patient Compliance | 2 | 2015 | 202 | 0.210 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2001 | 16 | 0.210 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2021 | 7 | 0.210 |
Why?
|
| Homosexuality, Male | 2 | 2019 | 438 | 0.210 |
Why?
|
| Survival Rate | 5 | 2014 | 310 | 0.200 |
Why?
|
| Lupus Nephritis | 2 | 2012 | 22 | 0.200 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2013 | 52 | 0.200 |
Why?
|
| Retrospective Studies | 7 | 2023 | 1961 | 0.200 |
Why?
|
| Rheumatology | 2 | 2013 | 15 | 0.190 |
Why?
|
| Aged, 80 and over | 8 | 2019 | 2333 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 592 | 0.190 |
Why?
|
| Veterans | 1 | 2022 | 115 | 0.190 |
Why?
|
| Polyamines | 1 | 2020 | 28 | 0.190 |
Why?
|
| Program Evaluation | 2 | 2013 | 316 | 0.190 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 336 | 0.190 |
Why?
|
| Antirheumatic Agents | 2 | 2018 | 33 | 0.180 |
Why?
|
| Life Expectancy | 1 | 2019 | 41 | 0.180 |
Why?
|
| Primary Health Care | 2 | 2015 | 283 | 0.180 |
Why?
|
| Hypertension | 4 | 2017 | 770 | 0.180 |
Why?
|
| Quality Control | 1 | 2019 | 35 | 0.170 |
Why?
|
| Kidney Transplantation | 2 | 2017 | 85 | 0.170 |
Why?
|
| Healthcare Disparities | 2 | 2014 | 446 | 0.170 |
Why?
|
| Astrocytes | 1 | 2020 | 203 | 0.170 |
Why?
|
| Dideoxynucleosides | 1 | 2018 | 11 | 0.170 |
Why?
|
| Glomerular Filtration Rate | 5 | 2023 | 137 | 0.170 |
Why?
|
| Electronic Health Records | 1 | 2019 | 65 | 0.160 |
Why?
|
| Models, Theoretical | 1 | 2019 | 210 | 0.160 |
Why?
|
| United States Dept. of Health and Human Services | 2 | 2014 | 9 | 0.160 |
Why?
|
| Obesity | 2 | 2016 | 965 | 0.160 |
Why?
|
| Living Donors | 1 | 2017 | 15 | 0.150 |
Why?
|
| Melanoma | 1 | 2018 | 91 | 0.150 |
Why?
|
| Graft Rejection | 1 | 2017 | 38 | 0.150 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 151 | 0.150 |
Why?
|
| Prospective Studies | 4 | 2015 | 1353 | 0.140 |
Why?
|
| Disease Progression | 3 | 2023 | 580 | 0.140 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2016 | 2 | 0.140 |
Why?
|
| Pancytopenia | 1 | 2015 | 3 | 0.140 |
Why?
|
| Kidney Diseases | 2 | 2011 | 159 | 0.140 |
Why?
|
| Risk Assessment | 4 | 2021 | 727 | 0.140 |
Why?
|
| Patient Care | 1 | 2016 | 28 | 0.140 |
Why?
|
| Kidney | 2 | 2023 | 322 | 0.140 |
Why?
|
| Geography | 1 | 2016 | 86 | 0.140 |
Why?
|
| Memory Disorders | 1 | 2016 | 65 | 0.130 |
Why?
|
| Insurance, Health | 2 | 2013 | 120 | 0.130 |
Why?
|
| Kidney Function Tests | 2 | 2017 | 30 | 0.130 |
Why?
|
| Autoantibodies | 3 | 2006 | 103 | 0.130 |
Why?
|
| School Health Services | 1 | 2015 | 77 | 0.130 |
Why?
|
| Chi-Square Distribution | 3 | 2013 | 213 | 0.120 |
Why?
|
| Age Factors | 5 | 2021 | 1007 | 0.120 |
Why?
|
| Bursitis | 1 | 2014 | 2 | 0.120 |
Why?
|
| Books | 1 | 2013 | 4 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 73 | 0.120 |
Why?
|
| Poverty | 2 | 2013 | 316 | 0.120 |
Why?
|
| Government Programs | 1 | 2013 | 28 | 0.120 |
Why?
|
| Prognosis | 4 | 2017 | 707 | 0.120 |
Why?
|
| Sex Factors | 4 | 2014 | 859 | 0.120 |
Why?
|
| Adolescent Behavior | 1 | 2015 | 243 | 0.110 |
Why?
|
| Rheumatic Diseases | 1 | 2013 | 9 | 0.110 |
Why?
|
| Osteoarthritis, Knee | 1 | 2013 | 10 | 0.110 |
Why?
|
| Hand | 1 | 2013 | 23 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2015 | 165 | 0.110 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 58 | 0.110 |
Why?
|
| Osteoarthritis | 1 | 2013 | 17 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 176 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 54 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2013 | 53 | 0.110 |
Why?
|
| Managed Care Programs | 1 | 2013 | 35 | 0.110 |
Why?
|
| Substance-Related Disorders | 1 | 2019 | 685 | 0.110 |
Why?
|
| Regression Analysis | 4 | 2015 | 429 | 0.110 |
Why?
|
| Raynaud Disease | 2 | 2010 | 10 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2013 | 121 | 0.100 |
Why?
|
| Age Distribution | 3 | 2021 | 223 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 531 | 0.100 |
Why?
|
| Immunosuppressive Agents | 2 | 2010 | 72 | 0.100 |
Why?
|
| Hepacivirus | 2 | 2013 | 59 | 0.100 |
Why?
|
| Risk | 2 | 2021 | 256 | 0.100 |
Why?
|
| Health Behavior | 2 | 2016 | 491 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 316 | 0.090 |
Why?
|
| Logistic Models | 4 | 2015 | 894 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 1426 | 0.090 |
Why?
|
| Odds Ratio | 4 | 2016 | 517 | 0.090 |
Why?
|
| Respiratory Function Tests | 1 | 2010 | 49 | 0.090 |
Why?
|
| Cyclophosphamide | 1 | 2010 | 52 | 0.090 |
Why?
|
| Time Factors | 5 | 2016 | 1681 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2010 | 56 | 0.090 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2008 | 4 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2013 | 653 | 0.080 |
Why?
|
| Weight Gain | 2 | 2021 | 128 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2017 | 1056 | 0.080 |
Why?
|
| Health Services | 1 | 2008 | 53 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 781 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2008 | 196 | 0.080 |
Why?
|
| Demography | 3 | 2016 | 167 | 0.080 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2006 | 14 | 0.070 |
Why?
|
| Aging | 2 | 2022 | 639 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 964 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2018 | 322 | 0.070 |
Why?
|
| Chemokine CCL5 | 1 | 2006 | 38 | 0.070 |
Why?
|
| HIV-1 | 3 | 2017 | 678 | 0.070 |
Why?
|
| Continuity of Patient Care | 2 | 2019 | 90 | 0.070 |
Why?
|
| Longitudinal Studies | 3 | 2015 | 841 | 0.060 |
Why?
|
| Serositis | 1 | 2003 | 1 | 0.060 |
Why?
|
| Pneumococcal Vaccines | 1 | 2003 | 13 | 0.060 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 13 | 0.060 |
Why?
|
| Health Status Disparities | 1 | 2010 | 583 | 0.060 |
Why?
|
| Recurrence | 1 | 2003 | 125 | 0.060 |
Why?
|
| Photosensitivity Disorders | 2 | 1999 | 3 | 0.060 |
Why?
|
| Creatinine | 1 | 2023 | 101 | 0.060 |
Why?
|
| DNA, Viral | 1 | 2023 | 295 | 0.050 |
Why?
|
| Gender Identity | 1 | 2022 | 93 | 0.050 |
Why?
|
| Liver | 2 | 2019 | 447 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2021 | 55 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2021 | 91 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 608 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 150 | 0.050 |
Why?
|
| Histiocytic Necrotizing Lymphadenitis | 1 | 2001 | 3 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2011 | 424 | 0.050 |
Why?
|
| Eflornithine | 1 | 2020 | 18 | 0.050 |
Why?
|
| Spermidine | 1 | 2020 | 31 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 217 | 0.050 |
Why?
|
| Spermine | 1 | 2020 | 64 | 0.050 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2019 | 5 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 26 | 0.040 |
Why?
|
| Sunscreening Agents | 1 | 1999 | 9 | 0.040 |
Why?
|
| Protein Transport | 1 | 2020 | 286 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 341 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 51 | 0.040 |
Why?
|
| Sunlight | 1 | 1999 | 46 | 0.040 |
Why?
|
| Alcoholism | 1 | 2021 | 220 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 269 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2017 | 23 | 0.040 |
Why?
|
| Graft Survival | 1 | 2017 | 34 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2017 | 74 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2020 | 1442 | 0.040 |
Why?
|
| South America | 1 | 2016 | 16 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2016 | 151 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2020 | 1534 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 28 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2017 | 182 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2017 | 231 | 0.030 |
Why?
|
| Socioeconomic Factors | 2 | 2010 | 1003 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2020 | 1149 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2014 | 39 | 0.030 |
Why?
|
| Health Policy | 1 | 2016 | 149 | 0.030 |
Why?
|
| Unemployment | 1 | 2014 | 23 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2016 | 205 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2014 | 74 | 0.030 |
Why?
|
| Rats | 2 | 2020 | 3261 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2015 | 228 | 0.030 |
Why?
|
| Research Design | 1 | 2016 | 292 | 0.030 |
Why?
|
| Foodborne Diseases | 1 | 2013 | 22 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2019 | 587 | 0.030 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2013 | 2 | 0.030 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2013 | 5 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2014 | 91 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 628 | 0.030 |
Why?
|
| Histone Deacetylase 1 | 1 | 2013 | 14 | 0.030 |
Why?
|
| Office Visits | 1 | 2013 | 22 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2013 | 117 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2013 | 109 | 0.030 |
Why?
|
| Animals | 4 | 2020 | 14307 | 0.030 |
Why?
|
| Social Class | 1 | 2014 | 228 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2016 | 490 | 0.030 |
Why?
|
| Complement C4 | 1 | 2011 | 5 | 0.030 |
Why?
|
| Biopsy | 1 | 2012 | 151 | 0.030 |
Why?
|
| Community Health Services | 1 | 2013 | 175 | 0.030 |
Why?
|
| Proteinuria | 1 | 2011 | 48 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 229 | 0.020 |
Why?
|
| Base Sequence | 1 | 2013 | 932 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 391 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 484 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 413 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 897 | 0.020 |
Why?
|
| Quality of Life | 1 | 2014 | 459 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 1490 | 0.020 |
Why?
|
| DNA | 2 | 2006 | 549 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2010 | 80 | 0.020 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2007 | 9 | 0.020 |
Why?
|
| Forms and Records Control | 1 | 2007 | 5 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2007 | 18 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 212 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 2007 | 18 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2007 | 36 | 0.020 |
Why?
|
| Chemokine CCL3 | 1 | 2006 | 13 | 0.020 |
Why?
|
| Chemokine CCL4 | 1 | 2006 | 18 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 2128 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 528 | 0.020 |
Why?
|
| snRNP Core Proteins | 1 | 2006 | 11 | 0.020 |
Why?
|
| Glycoside Hydrolases | 1 | 1975 | 6 | 0.020 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2006 | 12 | 0.020 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (GTP) | 1 | 1975 | 3 | 0.020 |
Why?
|
| Schizosaccharomyces | 1 | 1975 | 11 | 0.020 |
Why?
|
| Ribonucleoproteins | 1 | 2006 | 29 | 0.020 |
Why?
|
| Ascomycota | 1 | 1975 | 15 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 147 | 0.020 |
Why?
|
| Digitoxin | 1 | 1975 | 7 | 0.020 |
Why?
|
| Autoantigens | 1 | 2006 | 82 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 1975 | 69 | 0.020 |
Why?
|
| Mice | 1 | 2013 | 5668 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2001 | 58 | 0.010 |
Why?
|
| Prednisone | 1 | 2001 | 26 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2001 | 213 | 0.010 |
Why?
|
| Age of Onset | 1 | 2000 | 98 | 0.010 |
Why?
|
| Clothing | 1 | 1999 | 6 | 0.010 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 1999 | 5 | 0.010 |
Why?
|
| Exanthema | 1 | 1999 | 9 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2001 | 137 | 0.010 |
Why?
|
| Arthritis | 1 | 1999 | 16 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 1999 | 67 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 1999 | 111 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 1999 | 116 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1999 | 48 | 0.010 |
Why?
|
| Kinetics | 2 | 1975 | 650 | 0.010 |
Why?
|
| Chromatography, DEAE-Cellulose | 1 | 1975 | 8 | 0.000 |
Why?
|
| Oxaloacetates | 1 | 1975 | 2 | 0.000 |
Why?
|
| Phenanthrolines | 1 | 1975 | 4 | 0.000 |
Why?
|
| Mercaptoethanol | 1 | 1975 | 13 | 0.000 |
Why?
|
| Ribonucleotides | 1 | 1975 | 4 | 0.000 |
Why?
|
| Pyruvates | 1 | 1975 | 5 | 0.000 |
Why?
|
| Gluconates | 1 | 1975 | 5 | 0.000 |
Why?
|
| 2,2'-Dipyridyl | 1 | 1975 | 6 | 0.000 |
Why?
|
| Chromatography, Gel | 1 | 1975 | 46 | 0.000 |
Why?
|
| Lactones | 1 | 1975 | 20 | 0.000 |
Why?
|
| Digitoxigenin | 1 | 1975 | 4 | 0.000 |
Why?
|
| Hydroxylation | 1 | 1975 | 14 | 0.000 |
Why?
|
| NADP | 1 | 1975 | 24 | 0.000 |
Why?
|
| Chromatography, Thin Layer | 1 | 1975 | 37 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1975 | 161 | 0.000 |
Why?
|
| Polysaccharides | 1 | 1975 | 55 | 0.000 |
Why?
|
| Manganese | 1 | 1975 | 59 | 0.000 |
Why?
|
| Quinolines | 1 | 1975 | 60 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1975 | 120 | 0.000 |
Why?
|
| Magnesium | 1 | 1975 | 95 | 0.000 |
Why?
|
| Chickens | 1 | 1975 | 123 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1975 | 342 | 0.000 |
Why?
|
| Enzyme Activation | 1 | 1975 | 423 | 0.000 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1975 | 193 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1975 | 360 | 0.000 |
Why?
|
| Calcium | 1 | 1975 | 445 | 0.000 |
Why?
|